Christopher David Taves, a Director, acquired 345,000 Common Shares on a direct ownership basis at a price of $0.580 through a prospectus or prospectus exempt offering on March 5th, 2021. The insider also acquired 345,000 Warrants with an exercise price of $0.700 for 24 months. This represents a $200,100 investment into the company's shares and an account share holdings change of greater than 100%.
In addition, Christopher John Halyk, a Director, acquired 86,000 Common Shares and 86,000 Warrants on a direct ownership basis. This represents a $49,880 investment into the company's shares and an account share holdings change of greater than 100%.
MediPharm Labs is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.
Medipharm Labs Corp, formerly known as POCML 4 Inc, is a Canada-based medicinal cannabis company specializing in the pharmaceutical grade production of cannabis. The Company is focused on distillation and cannabinoid isolation and purification. The Company actively builds an inventory of specialized consumer products in anticipation of federal legalization of the adult-use market in Canada. Outside of the Canadian market, the Company develops MediPharm Labs Australia facility, which is a purpose-built and component of the Company's international investments. The Company operates with a processing capacity of approximately 100,000 kilograms of dry cannabis flower and trim per year.
No Comments